The Geography of Trust, Part 2: What Medical Tourism Patients Don’t Ask Before They Travel

Caleb Bartlett

This is the second piece in NestHeal’s Geography of Trust series. The first examined what actually earns a patient’s trust before they choose where to receive care. This one picks up after that choice is made, when two questions surface that most patients don’t think to ask until it’s too late to ask them comfortably: what happens if something goes wrong, and what happens to their medical information once it crosses a border. The reporting behind it draws on peer-reviewed clinical studies, government and public-health agency data — the US Centers for Disease Control and Prevention, the UK’s Office for National Statistics and Foreign, Commonwealth & Development Office — named case reporting from coroners’ inquests, and industry data, which is identified as industry data everywhere it appears. A claim resting on a single source, or on a party with a financial stake in the outcome, is marked as such.

Search “medical tourism risk” and the results cluster around a handful of stories: a Brazilian Butt Lift that went wrong in Istanbul, a tummy tuck death in Punta Cana, a UK government TikTok campaign warning citizens away from Turkey. These stories are real, and the patients at the center of them deserve more than a statistic. They’ve also narrowed the conversation down to one procedure and two countries, and that narrowing obscures the two questions that actually determine whether a patient’s trust was well placed: what a given procedure carries for risk, and what protections exist if that risk becomes reality.

The honest starting point is one the headlines skip. Most medical tourism isn’t cosmetic surgery, and most of it goes well.

The Majority of Medical Tourism, Quietly Succeeding

Industry market reports disagree sharply on how large medical tourism actually is — Global Market Insights values the 2025 market at $76.1 billion, while Fortune Business Insights puts the same year at $38.2 billion, roughly half that figure, and estimates of annual patient volume span from 14 million to 24 million depending on which research firm is counting. Those numbers are worth treating as contested estimates, not settled facts. What the competing reports agree on is the shape of the market underneath them: dental care, cardiac procedures, orthopedic surgery, fertility treatment and oncology care make up most of medical tourism. Cosmetic surgery is a meaningful minority, not the center of gravity that headline coverage suggests.

Costa Rica’s dental tourism sector is one of the more established examples. The Costa Rican College of Dentists is reported, via a secondary industry source, to put implant success rates around 95 percent — a figure worth verifying directly before it’s treated as settled, but directionally consistent with the country’s decades-long dental-tourism reputation. Cardiac programs in India and Turkey are regularly cited, in industry cost analyses, for delivering procedures comparable to US standards of care at a fraction of US pricing, which is the economic logic driving much of the sector’s real growth.

That said, success stories alone would be as incomplete a picture as horror stories alone. A nationwide Brazilian study, published in BMC Cardiovascular Disorders and drawing on records for 78,808 patients who underwent heart valve surgery in Brazil’s public health system, found medium-term outcomes that lagged what’s typically reported in high-income countries. That finding isn’t included here to undercut the success stories above it — it’s included because it’s the kind of number that exists precisely because someone built a system to track it honestly, rather than market it. That distinction, between outcomes a country can show you and outcomes a country tells you about, turns out to be the article’s real throughline, and it resurfaces later in the discussion of data transparency.

The Procedures That Carry Real Risk, Wherever They Happen

The most instructive numbers in this conversation come entirely from inside the United States, with no passport involved. The field-defining liposuction mortality study, led by Frederick Grazer and Rudolph de Jong and published in Plastic and Reconstructive Surgery in 2000, remains a touchstone two decades later because of what it found: pulmonary and fat embolism were the leading cause of death, not infection, not hygiene, not anything tied to where the procedure happened.

Brazilian Butt Lift procedures have drawn particular scrutiny since. A survey of 692 surgeons conducted by the Aesthetic Surgery Education and Research Foundation’s Task Force (Mofid et al., Aesthetic Surgery Journal, 2017), covering 198,857 gluteal fat-grafting cases, put annual mortality at roughly 1 in 3,448, with individual surgeon-reported estimates ranging from 1 in 2,351 to 1 in 6,241 — figures the Task Force itself flagged as likely affected by a low survey response rate. A narrower, autopsy-based study grounded entirely in South Florida medical examiner records (Pazmiño and Garcia, Aesthetic Surgery Journal, 2023) found 25 BBL-related fat-embolism deaths between 2010 and 2022, 14 of them occurring after the field’s 2018 safety guidelines and Florida’s 2019 rule restricting the procedure to subcutaneous injection only. Every one of those 25 deaths happened in a US jurisdiction, under US medical licensing, with no border crossed anywhere in the data.

This is the evidence that should anchor the rest of the conversation: BBL and extensive combined-procedure surgery carry serious, well-documented risk in Miami as much as in Istanbul. The variable that matters most is which procedure a patient is having and under what conditions it’s performed — not which country’s airport they land in.

When Care Crosses a Border: Two Patterns, Not a Verdict

Two cases have shaped most of the public conversation about medical tourism risk, and both are worth examining honestly — not as a verdict on a country, but as illustrations of what happens when the procedure risk above meets a particular way of selling and delivering care.

The UK’s Foreign, Commonwealth & Development Office has tracked a rising count of British deaths following medical procedures in Turkey: 28 since 2019 through March 2024, according to a Hansard statement by Foreign Office minister Leo Docherty, with GOV.UK’s live travel-advice page now noting 7 more in 2025. That count has an important limit built into it — it only reflects deaths known to UK consular staff, not a rate, because no official figure exists for how many Britons travel to Turkey for treatment each year. The one Turkey-specific visit estimate in circulation, roughly 200,000 in 2024, appears only in sponsored content and has not been verified against official statistics. Coroners examining the named cases have documented real, specific failures: Melissa Kerr was not seen by a surgeon before the day of her procedure; Hayley Dowell was offered a discounted BBL with, in her family’s account, five minutes to decide and a card machine in hand; Demi Agoglia’s death was ruled misadventure “contributed to by neglect,” with her aftercare described in the inquest as woeful. Of roughly a dozen named deaths since 2019, about five involved BBL procedures and about four involved bariatric surgery — a split that complicates any version of this story that blames one procedure alone.

It also complicates a simple “come home, it’s safer” conclusion. The Royal College of Surgeons wrote an open letter in August 2026 pointing out that any doctor registered with the General Medical Council can still legally perform breast augmentation, rhinoplasty, facelifts and liposuction in the UK without being on the specialist register — thirteen years after a government review first flagged the gap. Alice Webb died in Gloucester in 2024 after a non-surgical “liquid BBL” performed by a practitioner who, the BBC later reported, had already been banned from the procedure in two other areas. The UK’s own public-awareness campaign, launched with TikTok in August 2025, doesn’t name Turkey anywhere in its text — it launched the same week as a domestic crackdown on unregulated non-surgical BBLs, which suggests the government’s own framing is about procedure and practice standards more than nationality.

The United States has its own version of this story. The CDC’s January 2024 MMWR report counted 93 US citizen deaths following cosmetic surgery in the Dominican Republic between 2009 and 2022, and a 2026 follow-up in Emerging Infectious Diseases reviewed 21 further reports covering roughly 145 patients with adverse outcomes. The CDC was explicit about what it couldn’t conclude: “no reliable statistics on the number of U.S. citizens who receive cosmetic surgery in the Dominican Republic each year are available, precluding calculation of the risk for perioperative death.” That sentence, from the US government’s own public-health agency, is worth sitting with. A government can count deaths without being able to say whether a country is more dangerous than any other — and the honest position, which the CDC took and the FCDO’s own figures imply without quite stating, is to say so rather than let a raw count carry the weight of a rate it cannot support.

What Happens After: Complication Management and Recourse

When a complication does appear — in Miami or Istanbul alike — what happens next depends heavily on where the patient is standing when it does. The AMA Journal of Ethics has been direct about this: once a patient leaves the country where a procedure was performed, they are generally no longer protected by that country’s legal system in any straightforward way, and a US court will typically decline jurisdiction over a foreign provider entirely. Pursuing a claim abroad usually means hiring a local specialist lawyer at the patient’s own expense, a step few patients plan for before they travel. A 2023 UK case is a rare exception that proves the rule: a British court found a surgeon and clinic jointly and severally liable, in an outcome analyzed by the law firm Bevan Brittan, but that result took years of litigation that most patients can’t or won’t pursue.

A niche complication-insurance market has emerged to fill part of this gap. Several vendors now sell coverage for revision surgery, extended stays and repatriation, typically priced around 1 to 5 percent of the procedure cost. These are commercial products, worth treating as such rather than as a guarantee: the better policies are explicit about what triggers a payout and what time limit applies, and the scenario patients cite most often as uncovered is the complication that appears weeks after they’ve already flown home — which is, not coincidentally, the exact moment distance from the original provider is at its greatest.

The Trust Factor Hiding in Plain Sight: Data and Transparency

The questions above — what happens to a patient physically if something goes wrong — have at least some public data behind them. The question of what happens to a patient’s information has almost none, and it may be the least-discussed trust factor in the entire medical tourism conversation.

HIPAA, the law most American patients assume protects their medical records, stops at the US border. As the health-compliance publication Paubox has noted, citing reporting in Medical Tourism Magazine, HIPAA does not apply to medical information obtained outside the United States. A patient’s records, once created in a clinic abroad, fall instead under whatever privacy law that country has — and the CDC’s own Yellow Book warns that in some destinations, formal medical-record privacy and security policies aren’t standard practice at all. The picture is more protected on paper for patients from the EU, where GDPR’s Articles 44 through 50 govern how personal data can leave the bloc, and more complicated in practice everywhere else: health systems globally now navigate something like 144 distinct national privacy regimes, by one count from the health-data newsletter Partners in Digital Health, with no single standard a patient can rely on regardless of where they’re treated.

The same transparency gap shows up on the provider side, and it may be the more consequential version, because it’s the one patients could actually act on if it were visible. The Brazilian cardiac study cited earlier is unusual precisely because it exists: a nationwide, independently tracked registry, publishing real outcome data whether or not that data flatters the system it describes. Compare that to the success-rate claims circulating in hospital and facilitator marketing for cardiac programs elsewhere — claims of 98, even 99 percent, published on hospital blogs and facilitator sites with no named methodology, no independent audit, and no comparison population attached. Both things can be true at once: a hospital’s outcomes might genuinely be excellent, and its marketed number might still be unverifiable as published. The distance between “this hospital says its success rate is 98 percent” and “an independent registry tracked this hospital’s outcomes and found a 98 percent success rate” is the entire distance between a marketed signal and a verified one — the same distance Part 1 of this series found separating an accreditation logo from the trust patients actually place in a provider.

Completing the Geography of Trust

Put together, the evidence points away from a simple story. Trust isn’t established by avoiding a particular country. It’s established by understanding what a specific procedure actually carries for risk, planning honestly — before departure, not after a complication appears — for what recourse exists if something goes wrong, and insisting on verification wherever a number is doing the work of reassurance: a success rate, a security certification, a data-handling policy. A patient who asks what happens to their information and what happens if the surgery doesn’t go as planned is asking a more useful question than “which country is safe,” and a provider who can answer both clearly has already done more to earn trust than any accreditation seal or destination campaign can do on its own.

Questions Worth Asking

For Healthcare Teams Building Trust With International Patients

Ask yourselves:

• Can we publish a plain-language, patient-specific data-handling policy today, or does our current policy require a lawyer to parse?

• Is our information-security standard something we’ve earned and can point to, or something we simply claim?

• Do we give patients a portable copy of their own records before they leave, as a matter of course rather than a special request?

• Do we disclose, clearly, which third parties — facilitators, insurers, partner clinics — see a patient’s data, and why?

• Is our published outcome data independently audited, or is it self-reported?

• Do we have one named, reachable person a patient can contact after they’ve returned home — and does that person actually respond?

Ask your patients, before they sign anything:

• Have we told them plainly what their specific procedure’s documented risk is, independent of where they have it done?

• Have we explained what cross-border legal recourse does and doesn’t look like, in plain terms, before they commit?

• Have we been specific about what our complication-insurance options actually exclude, not just what they cover?

For Patients

Ask yourself:

• Am I choosing this provider because of its procedure-specific outcome data, or because of its marketing?

• Have I asked what happens to my medical records after I leave the country where I was treated?

• Do I know, concretely, what my recourse looks like if a complication appears after I’ve flown home?

Ask the provider:

• Can you show me independently audited outcome data for this specific procedure — not just a marketed success rate?

• Who sees my medical information, and under which country’s privacy law?

• If something goes wrong after I’ve returned home, who exactly do I call, and what will they actually do?

Policies

Editorial Policy

Fact-Checking Policy

Corrections Policy

Ethics Policy